Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. was founded in 2010 and is headquartered in Wuhan, China.
Metrics to compare | 2496 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship2496PeersSector | |
---|---|---|---|---|
P/E Ratio | −10.3x | −21.8x | −0.5x | |
PEG Ratio | −0.20 | 0.18 | 0.00 | |
Price/Book | 33.0x | 6.3x | 2.6x | |
Price / LTM Sales | 9.3x | 20.7x | 3.3x | |
Upside (Analyst Target) | - | −10.2% | 38.7% | |
Fair Value Upside | Unlock | −12.3% | 5.0% | Unlock |